News

The agreement is for both Gelclair, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis (OM), and Soltamox (tamoxifen citrate) oral liquid solution,

The Phase II clinical trial of ‘tivozanib’ is intended for patients with locally recurrent or metastatic triple negative breast cancer (TNBC). AVEO, which was developing tivozanib in collaboration

Pursuant to the terms of the agreement, YODA will serve as an independent body to review requests from investigators and physicians seeking access to anonymized clinical trials data

As part of the partnership, Boehringer Ingelheim and Duke Clinical Research Institute will initiate a prospective, multi-center IPF registry in the US, as well as establish a biomarker

By capitalizing on CreaGen’s chemistry expertise and state-of-the-art laboratory facility, Empiriko is validating methodologies for its transformative Biomimiks technology. Now pharmaceutical customers, for the first time, can use

XBiotech will soon launch its Phase III registration study in Europe to evaluate Xilonix in patients with treatment-resistant colorectal cancer. Cancer treatment centers in at least 6 countries

iBio obtained an exclusive license to patents and related intellectual property for this novel therapy, and then entered a collaboration agreement with the Medical University of South Carolina

The NDA submission is based on a series of laboratory and clinical studies conducted by OptiNose in the US and Europe, including comparative bioavailability and phase II and

BAX 826 is a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness. The amended license